针对间日疟原虫消除的病灶性群体服药(FLAME):秘鲁开放标签整群随机对照试验研究方案
FLAME研究是一项为期3年的开放标签整群随机对照试验,在秘鲁洛雷托30个低传播社区中按1:1随机分配至病灶性群体服药(fMDA)组或对照组,评估fMDA减少间日疟原虫传播的效果与安全性。干预组高风险个体在2年内接受3个周期fMDA,每个周期含2轮直接观察治疗,间隔2个月;主要结局为有症状间日疟原虫疟疾的累积发病率。样本量基于α=0.05、变异系数k=0.87,提供80%把握度检测至少68%的相对下降。
要点
- 在秘鲁洛雷托30个低传播社区(API<250例/1000人)比较fMDA与标准疟疾控制措施。
- fMDA组高风险个体接受3个周期治疗,每周期2轮直接观察治疗,间隔2个月。
- ≥16岁者用氯喹25 mg/kg加单剂替诺喹300 mg; younger者用氯喹25 mg/kg加伯氨喹0.5 mg/kg/天×7天。
核心结论
- 该试验将生成关于fMDA用于间日疟原虫的证据,为秘鲁及类似流行区的疟疾消除工作提供信息。
- 研究结果将通过同行评议出版物以及秘鲁和国际研究论坛的利益相关者会议传播。
研究设计与样本
- FLAME研究是一项为期3年的开放标签整群随机对照试验,旨在确定fMDA减少间日疟原虫传播的影响和安全性。
- 研究在秘鲁洛雷托开展,当地标准干预已减少间日疟原虫病例,但由于高比例亚临床感染,传播持续存在。
- 30个低传播社区(API<250例/1000人)采用限制性随机化按1:1随机分配至fMDA组或对照组。
- 所有社区均接受秘鲁国家标准化疟疾控制措施。
- 干预组中高风险个体(过去2年内报告的间日疟原虫病例居住地200米以内)且无研究药物禁忌证(包括G6PD缺乏症)者,在2年内接受3个周期fMDA。
主要发现
- 主要结局为有症状间日疟原虫疟疾的累积发病率。
- 样本量基于α=0.05和变异系数(k)=0.87,提供80%把握度检测累积间日疟原虫发病率至少68%的相对下降。
- 次要结局包括安全性、成本效果以及感染患病率和血清阳性率,通过年度横断面调查评估。
- 安全性通过被动和主动药物警戒评估,包括在样本中通过评估贫血和血尿来筛查治疗后G6PD相关溶血。
关键数值与推荐
- fMDA方案:≥16岁个体接受氯喹(CQ)25 mg/kg加单剂替诺喹(TQ)300 mg; younger个体接受氯喹25 mg/kg加伯氨喹(PQ)0.5 mg/kg/天×7天。
- 每个fMDA周期包括2轮直接观察治疗,间隔2个月给药。
- 高风险个体定义为过去2年内报告的间日疟原虫病例居住地200米以内者。
- 低传播社区定义为API<250例/1000人。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outside of sub-Saharan Africa, Plasmodium vivax has become the dominant species of malaria. Focal mass drug administration (fMDA) is a potential strategy to support elimination efforts, but controlled studies are lacking. METHODS: The FocaL mass drug Administration for Plasmodium vivax Malaria Elimination (FLAME) study is a 3-year cluster randomized controlled trial to determine the impact and safety of fMDA to reduce P. vivax transmission. The study will be conducted in Loreto, Peru, where standard interventions have reduced P. vivax cases, but transmission persists due to a high proportion of subclinical infections. Thirty low transmission communities (API < 250 cases/1000 population) will be randomized 1:1 to fMDA versus control using a restricted randomization. All communities will receive Peruvian national standard malaria control measures. In the intervention arm, high-risk individuals (living within 200 m of a P. vivax case reported in the prior 2 years) without contraindication to study medications, including G6PD deficiency, will receive three cycles of fMDA over a 2-year period. Each cycle will include two rounds of directly observed therapy delivered 2 months apart. The fMDA regimen will include 25 mg/kg chloroquine (CQ) plus a single 300 mg dose of tafenoquine (TQ) for individuals age ≥ 16 years, and 25 mg/kg of CQ plus 7 days of 0.5 mg/kg/day of primaquine (PQ) if younger. The primary outcome is the cumulative incidence of symptomatic P. vivax malaria. The sample size provides 80% power to detect at least a 68% relative reduction in cumulative P. vivax incidence, based on alpha of 0.05 and a coefficient of variation (k) of 0.87. Secondary outcomes include safety, cost-effectiveness, and infection prevalence and seroprevalence which will be assessed in annual cross-sectional surveys. Safety will be assessed in passive and active pharmacovigilance, including post-treatment screening for G6PD-associated hemolysis by assessing for anemia and hematuria in a sample. DISCUSSION: The trial will generate evidence regarding fMDA for P. vivax and inform malaria elimination efforts in Peru and similarly endemic settings. Findings will be disseminated in peer-reviewed publications and through stakeholder meetings in Peruvian and international research forums. TRIAL REGISTRATION: Clinicaltrials.gov NCT05690841. This trial was registered on 09 January 2023. Peruvian Clinical Trial Registry (REPEC) 020-23. This trial was registered on 21 February 2024.
引用
- Fine SR, Soto Calle V, Altamirano Quiroz A, et al. FocaL mass drug administration for Plasmodium vivax malaria elimination (FLAME): study protocol for an open-label cluster randomized controlled trial in Peru. Trials. 2025. PMID: 41088393. doi:10.1186/s13063-025-09112-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。